Condition: Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma · Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The goal of this single-arm study is to explore the efficacy and safety of Adebrelimab in combination with Apatinib and Tegafur for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma that has failed first-line standard treatment with PD-1 inhibitors in combination with chemotherapy.
This description comes directly from the study's public registry record.
Minghui Wang · +86 13826276828 · wmingh@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06339619